Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 Eisai Sep 08, 2025 16:49 HKT/SGT Read More
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 Eisai Sep 04, 2025 09:56 HKT/SGT Read More
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status Eisai Sep 03, 2025 10:32 HKT/SGT Read More
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D Everest Medicines Limited Sep 01, 2025 21:55 JST Read More
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease Eisai Sep 01, 2025 12:44 HKT/SGT Read More
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma Eisai Aug 29, 2025 17:17 HKT/SGT Read More
Fujitsu develops AI agent platform for the healthcare sector to enhance operational efficiency and ensure stable medical service provision Fujitsu Ltd Aug 27, 2025 20:50 HKT/SGT Read More
Mitsubishi Corporation Invests in Fullerton Health Mitsubishi Corporation Aug 26, 2025 11:54 HKT/SGT Read More
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) Eisai Aug 25, 2025 18:30 HKT/SGT Read More
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers China Medical System Holdings Limited Aug 19, 2025 16:00 JST Read More
UNFPA and NEC Collaborate to Build Beneficiary Information Management and e-Voucher System NEC Corporation Aug 18, 2025 13:38 HKT/SGT Read More
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC Eisai Jul 31, 2025 08:30 HKT/SGT Read More
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease Eisai Jul 31, 2025 08:20 HKT/SGT Read More
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 Eisai Jul 31, 2025 08:10 HKT/SGT Read More
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma Eisai Jul 29, 2025 08:01 HKT/SGT Read More
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China China Medical System Holdings Limited Jul 29, 2025 05:00 JST Read More
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics Olympus Jul 25, 2025 16:00 JST Read More
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics Olympus Jul 25, 2025 15:00 HKT/SGT Read More
